PEPTIDE IGF-1 LR3
Axiom Peptides is using the most refined technology in order to obtain the highest quality and purity IGF-1 LR3 Peptide.
Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence ("arginine 3"), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) ("long"), for a total of 83 amino acids (relative to the 70 of IGF-1). The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has a very low affinity for insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability. As a result, it is approximately three times more potent than IGF-1 and possesses a significantly longer half-life of about 20–30 hours (relative to IGF-1's half-life of about 12–15 hours).
What is IGF 1 lr3 used for?
IGF 1 lr3 Cycle?
Frequency: 1 injection of 100mcg per day (after a workout or before bed)
Dose per vial : 1 x 100mcg (1 vial for 1 day)
Dose per injection: 100mcg=1mL (100 units on the insulin syringe)
IGF 1 lr3 Therapy cycle: 4 to 6 weeks.